Feed / EWTX

Edgewise Therapeutics, Inc.

EWTX

Healthcare · 44.20 +2.0% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

Edgewise Therapeutics, Inc.'s move is being confirmed by its market group.

EWTX accounts for 9.5% of the group's measured movement across 5.6 effective names. raw member direction is mixed; 7 of 12 session-normalized paths align to the upside. Capital-flow agreement is 16%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

Session-normalized 5m paths
Role in the moveAligned contributor#5 of 12 by movement share
Group movement share9.5%Absolute path energy—not portfolio weight
Relative path+2.16%aligned
Effective breadth5.6 / 12balanced
Relative alignment7/12upside path · 1 counter-moving
Capital-flow agreement16%not yet clean
SEQUENCE READ

EWTX was the first measured mover. EWTX crossed its material path threshold at 15:50 ET. AXSM, ALMS, GPCR followed.

EVIDENCE COVERAGE

10 of 16 members in Clinical Biopharmaceuticals are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • At least 11 of 16 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NBIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.

Watch this read

Who this business touches

The relationships behind EWTX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

CYTKCytokinetics, IncorporatedcompetitorMay 7, 2026

In the field of emerging treatments for HCM, competitors include Bristol-Myers Squibb (BMS), Cytokinetics, Imbria Pharmaceuticals, Lexicon Pharmaceuticals, and Celltrion, and Braveheart Bio.

CYTKCytokinetics, IncorporatedsupplierFeb 26, 2026

The effects of EDG-7500 on cardiac function overlap with some of the desirable attributes of the cardiac myosin inhibitors (CMIs) such as BMS’s CAMZYOS® (mavacamten) and Cytokinetics’ MYQORZO (aficamten).

Depended on by

CYTKCytokinetics, IncorporatedcompetitorFeb 26, 2026

In addition to Camzyos®, Edgewise Therapeutics, Lexicon, Tenaya and Braveheart Bio (Hengrui) are conducting clinical trials and could commercialize a drug that would compete with MYQORZO if successful.

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

EWTX is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.